BioCentury
ARTICLE | Finance

Ebb & Flow

August 16, 2004 7:00 AM UTC

Investors reacted badly to Monday's post-market news that Barr (BRL) will receive a license from Cephalon (CEPH) to sell generic oral transmucosal fentanyl starting Feb. 3, 2007.

CEPH was off $4.86 (10%) to $43 on Tuesday and closed the week down $6.07 (13%) at $42.01, even though the company said that were it not for the license, it probably would not have gone forward with its acquisition of Cima, which closed last week (see B3). ...